Characterization of TNBC patient–derived tumor xenografts
| Sample ID | Source | PTEN IHC (H-score) | PIK3CA status (MassArray) | BRCA status (Sanger) | PAM50 |
| TNBC1 | Metastatic | 0 | H1047R | Wild-type | Basal-like |
| TNBC2 | Metastatic | 0 | Wild-type | Wild-type | Basal-like/claudin-lowa |
| TNBC3 | Primary | 0 | Wild-type | Wild-type | Basal-like |
NOTE: Expression of PTEN and PIK3CA or BRCA1/2 mutational statuses of 3 tumor grafts derived from either primary or metastatic lesions of different patients with TNBCs. A minimum of 3 independent samples were used for PTEN quantification by immunohistochemistry. Molecular subtype analysis was conducted using PAM50 molecular analysis of Affymetrix microarrays.
Abbreviation: IHC, immunohistochemistry.
↵aLow estrogen receptor expression by IHC.